Pharming Group provides update on previously announced G&A expense reduction plan
Pharming (Euronext: PHARM; Nasdaq: PHAR) announced an organizational restructuring to accelerate growth and implement a previously disclosed G&A reduction plan.
The plan includes a 20% net reduction in non-commercial and non-medical headcount, primarily at its Netherlands headquarters, and targets 15% lower total G&A or approximately $10 million annually. The company expects one-time restructuring costs of about $7 million to be recorded in Q4 2025. Pharming said it consulted with its Dutch Works Council in line with Dutch labor law.
Pharming (Euronext: PHARM; Nasdaq: PHAR) ha annunciato una riorganizzazione aziendale per accelerare la crescita e attuare un piano di riduzione G&A già comunicato.
Il piano prevede una riduzione netta del 20% del personale non commerciale e non medico, principalmente presso la sede olandese, e punta a un costo totale G&A inferiore del 15% o circa 10 milioni di dollari all'anno. L'azienda prevede costi una tantum per riorganizzazione di circa 7 milioni di dollari da registrare nel quarto trimestre del 2025. Pharming ha detto di aver consultato il Dutch Works Council in linea con la legge sul lavoro olandese.
Pharming (Euronext: PHARM; Nasdaq: PHAR) anunció una reestructuración organizacional para acelerar el crecimiento e implementar un plan de reducción de G&A ya informado.
El plan incluye una reducción neta del 20% en el personal no comercial y no médico, principalmente en su sede de los Países Bajos, y apunta a un 15% menos de G&A total o aproximadamente 10 millones de dólares anuales. La compañía espera costes de reestructuración únicos de unos 7 millones de dólares que se registrarán en el cuarto trimestre de 2025. Pharming señaló que consultó con su Consejo de Trabajo holandés conforme a la legislación laboral de los Países Bajos.
Pharming (Euronext: PHARM; Nasdaq: PHAR)는 성장을 가속화하고 이전에 공시된 G&A 절감 계획을 실행하기 위한 조직 구조 개편을 발표했습니다.
계획에는 주로 네덜란드 본사의 비상업 및 비의료 직원을 중심으로 순 20% 감축이 포함되며, 총 G&A를 약 15% 낮추고 연간 약 1000만 달러에 달하는 것을 목표로 합니다. 회사는 약 700만 달러의 일회성 재구성 비용이 2025년 4분기에 기록될 것으로 예상합니다. Pharming은 네덜란드 노동법에 따라 네덜란드 노사협의회와 협의했다고 밝혔습니다.
Pharming (Euronext: PHARM; Nasdaq: PHAR) a annoncé une restructuration organisationnelle pour accélérer la croissance et mettre en œuvre un plan de réduction des coûts G&A déjà divulgué.
Le plan prévoit une réduction nette de 20% du personnel non commercial et non médical, principalement à son siège néerlandais, et vise une réduction totale des G&A de 15% ou environ 10 millions de dollars annuels. La société prévoit des coûts de restructuration uniques d'environ 7 millions de dollars à comptabiliser au cours du T4 2025. Pharming a déclaré avoir consulté le Dutch Works Council conformément au droit du travail néerlandais.
Pharming (Euronext: PHARM; Nasdaq: PHAR) hat eine organisatorische Umstrukturierung angekündigt, um das Wachstum zu beschleunigen und einen zuvor angekündigten G&A-Senkungsplan umzusetzen.
Der Plan sieht eine Netto-Reduktion von 20% bei nicht-kommerziellen und nicht-medizinischen Stellen vor, hauptsächlich am niederländischen Hauptsitz, und zielt auf eine um 15% niedrigere Gesamt-G&A oder rund 10 Millionen US-Dollar jährlich ab. Das Unternehmen erwartet einmalige Restrukturierungskosten von ca. 7 Millionen US-Dollar, die im vierten Quartal 2025 erfasst werden sollen. Pharming teilte mit, dass es sich gemäß dem niederländischen Arbeitsrecht mit dem Dutch Works Council beraten hat.
Pharming (Euronext: PHARM; Nasdaq: PHAR) أعلنت عن إعادة هيكلة تنظيمية لتسريع النمو وتنفيذ خطة تقليل G&A التي تم الكشف عنها سابقاً.
تشمل الخطة خفضاً صافياً بنسبة 20% في عدد الموظفين غير التجاريين وغير الطبيين، مع التركيز بشكل أساسي في المقر الهولندي، وتستهدف خفضاً إجمالياً في G&A بنسبة 15% أو نحو 10 ملايين دولار سنوياً. وتتوقع الشركة تكاليف إعادة هيكلة لمرة واحدة تبلغ نحو 7 ملايين دولار لتسجيلها في الربع الرابع من 2025. وقالت Pharming إنها استشارت مجلس العمل الهولندي تماشيًا مع قانون العمل الهولندي.
Pharming (Euronext: PHARM; Nasdaq: PHAR) 宣布进行组织架构调整，以加速增长并执行先前披露的 G&A 削减计划。
该计划包括在非商业和非医疗岗位的净减少 20%，主要在其荷兰总部，并以实现 总 G&A 下降 15% 或约每年 1000 万美元 为目标。公司预计在 2025 年第四季度记入大约 700 万美元的一次性重组成本。Pharming 表示其已按照荷兰劳动法与荷兰工作委员会进行了协商。
- Targeted G&A reduction of 15% / ~$10 million annually
- 20% net reduction in non-commercial/non-medical headcount
- Restructuring intended to optimize capital allocation and growth
- One-time restructuring charge of approximately $7 million in Q4 2025
- Headcount reductions concentrated at Netherlands headquarters may disrupt operations
Leiden, the Netherlands, October 6, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced the implementation of an organizational restructuring to accelerate the Company’s growth. The restructuring is aligned with our previously announced plan to reduce general and administrative (G&A) expenses to optimize capital allocation across the organization.
The restructuring includes a redesign of Pharming’s organizational structure and a
Pharming has consulted with its Dutch Works Council over the past several months, in accordance with Dutch labor law, regarding the organizational changes.
About Pharming Group N.V.
Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We are developing and commercializing a portfolio of innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, with a significant proportion of its employees based in the U.S.
For more information, visit www.pharming.com and find us on LinkedIn.
Forward-Looking Statements
This press release may contain forward-looking statements. Forward-looking statements are statements of future expectations that are based on management’s current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in these statements. These forward-looking statements are identified by their use of terms and phrases such as “aim”, “ambition”, ‘‘anticipate’’, ‘‘believe’’, ‘‘could’’, ‘‘estimate’’, ‘‘expect’’, ‘‘goals’’, ‘‘intend’’, ‘‘may’’, “milestones”, ‘‘objectives’’, ‘‘outlook’’, ‘‘plan’’, ‘‘probably’’, ‘‘project’’, ‘‘risks’’, “schedule”, ‘‘seek’’, ‘‘should’’, ‘‘target’’, ‘‘will’’ and similar terms and phrases. Examples of forward-looking statements may include statements with respect to timing and progress of Pharming's preclinical studies and clinical trials of its product candidates, Pharming's clinical and commercial prospects, and Pharming's expectations regarding its projected working capital requirements and cash resources, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Pharming's clinical trials and ramifications for the cost thereof; and clinical, scientific, regulatory, commercial, competitive and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in Pharming's 2024 Annual Report and the Annual Report on Form 20-F for the year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission, the events and circumstances discussed in such forward-looking statements may not occur, and Pharming's actual results could differ materially and adversely from those anticipated or implied thereby. All forward-looking statements contained in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Any forward-looking statements speak only as of the date of this press release and are based on information available to Pharming as of the date of this release. Pharming does not undertake any obligation to publicly update or revise any forward-looking statement as a result of new information, future events or other information.
Inside Information
This press release relates to the disclosure of information that qualifies, or may have qualified, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.
For further public information, contact:
Pharming Group, Leiden, the Netherlands
Michael Levitan, VP Investor Relations & Corporate Communications
T: +1 (908) 705 1696
Saskia Mehring, Corporate Communications Manager
T: +31 6 28 32 60 41
LifeSpring Life Sciences Communication, Amsterdam, the Netherlands
Leon Melens
T: +31 6 53 81 64 27
E: pharming@lifespring.nl
US PR
Ethan Metelenis
T: +1 (917) 882-9038E: Ethan.Metelenis@precisionaq.com
Attachment
FAQ
What G&A savings did Pharming (PHARM) target with the October 6, 2025 plan?
How many jobs will Pharming cut under the PHARM restructuring announced October 6, 2025?
When will Pharming record the restructuring costs for PHARM and how much?
Where are Pharming's (PHARM) headcount reductions primarily taking place?
Did Pharming consult employee representatives about the October 2025 restructuring?
